Maxim Group analyst Michael Okunewitch initiates coverage on Acrivon Therapeutics (NASDAQ:ACRV) with a Buy rating and announces Price Target of $24.
Related Posts
Footwear Company Caleres Issues 2026 Financial Targets Ahead Of Investor Day Event
Caleres Inc (NYSE:CAL) put forward its three-year strategic and financial plan in conjunction with its Oct. 5 Investor Day. The…
Wedbush Reiterates Outperform on Amazon.com, Maintains $180 Price Target
Wedbush analyst Scott Devitt reiterates Amazon.com (NASDAQ:AMZN) with a Outperform and maintains $180 price target.